We've just got to deliver what we've laid out here.

We did not deliver in the fourth quarter and that was unacceptable.

It's a great time to reinvest in our company. This action is yet another reflection of our commitment to enhance shareholder value.

We're just as frustrated as you are with the stock price.

Accelerating the growth in life sciences is key to our strategy to becoming a faster-growing, more profitable, less cyclical company.

Most of our businesses performed exceptionally well in spite of higher raw material costs and weak European currencies, with 11 of 18 strategic business units delivering double digit earnings growth.